Preclinical evaluation of MenB vaccines: Prerequisites for clinical development

Expert Review of Vaccines

Volumn 12, Issue 1, 2013, Pages 31-42

  Sanders, Holly ^a   Kaaijk, Patricia ^b   Van Den Dobbelsteen, Germie P J M ^a  

^a Janssen Research and Development   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Neisseria meningitidis; nonclinical; outer membrane vesicles; preclinical; vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

DRUG IMPURITY; DRUG MANUFACTURE; DRUG POTENCY; DRUG PURITY; DRUG QUALITY; DRUG STABILITY; DRUG STERILITY; IMMUNOGENICITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PRODUCT SAFETY; REVIEW;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; DRUG EVALUATION, PRECLINICAL; GUIDELINES AS TOPIC; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS, SEROGROUP B; VACCINES, CONJUGATE;

EID: 84871541601     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.137     Document Type: Review

References (93)

1. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2), 195-207; discussion 208 (1991).
2. de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340(8827), 1074-1078 (1992).
3. Arnold R, Galloway Y, McNicholas A, O'Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 29(40), 7100-7106 (2011).
4. Bjune G, Høiby EA, Grønnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338(8775), 1093-1096 (1991).
5. Caron F, Delbos V, Houivet E et al. Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine 30(34), 5059-5062 (2012).
6. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30(Suppl. 2), B87-B97 (2012).
7. Richmond PC, Marshall HS, Nissen MD et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, Phase 2 trial. Lancet Infect. Dis. 12(8), 597-607 (2012).
8. van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 25(13), 2491-2496 (2007).
9. Zollinger WD, Donets MA, Schmiel DH et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28(31), 5057-5067 (2010).
10. WHO. Guidelines on non-clinical evaluation of vaccines. WHO Technical Report Series 927, Annex 1 (2003).
11. European Medicines Agency. Note for Guidance: pre-clinical pharmacological and toxicological testing of vaccines. CPMP/SWP/465/95 (1997).
12. FDA. Guidance for Industry: Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical studies (1997).
13. European Commission. European Pharmacopoeia. Council of Europe, Strasbourg, France (2001).
14. van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13(4), 401-407 (1995).
15. Beernink PT, Shaughnessy J, Braga EM et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186(6), 3606-3614 (2011).
16. Jansen C, Wiese A, Reubsaet L et al. Biochemical and biophysical characterization of in vitro folded outer membrane porin PorA of Neisseria meningitidis. Biochim. Biophys. Acta 1464(2), 284-298 (2000).
17. Arigita C, Jiskoot W, Westdijk J et al. Stability of mono-and trivalent meningococcal outer membrane vesicle vaccines. Vaccine 22(5-6), 629-642 (2004).
18. Martino A, Magagnoli C, De Conciliis G et al. Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: an investigational vaccine component against Neisseria meningitidis. Vaccine 30(7), 1330-1342 (2012).
19. Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. Methods Mol. Med. 66, 81-107 (2001).
20. van de Waterbeemd B, Streefland M, van der Ley P et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28(30), 4810-4816 (2010).
21. van de Waterbeemd B, Streefland M, Van Keulen L et al. Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis. Vaccine 30(24), 3683-3690 (2012).
22. Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14(10), 1001-1008 (1996).
23. Arigita C, Kersten GF, Hazendonk T, Hennink WE, Crommelin DJ, Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine 21(9-10), 950-960 (2003).
24. Fukasawa LO, Gorla MC, Schenkman RP et al. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine 17(23-24), 2951-2958 (1999).
25. Gorringe A, Halliwell D, Matheson M, Reddin K, Finney M, Hudson M. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Vaccine 23(17-18), 2210-2213 (2005).
26. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459), 1816-1820 (2000).
27. Sun Y, Li Y, Exley RM et al. Identification of novel antigens that protect against systemic meningococcal infection. Vaccine 23(32), 4136-4141 (2005).
28. Humphries HE, Williams JN, Blackstone R et al. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine 24(1), 36-44 (2006).
29. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103(29), 10834-10839 (2006).
30. Vipond C, Wheeler JX, Jones C, Feavers IM, Suker J. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Hum. Vaccin. 1(2), 80-84 (2005).
31. Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 6(11), 3400-3413 (2006).
32. Tsolakos N, Lie K, Bolstad K et al. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media. Vaccine 28(18), 3211-3218 (2010).
33. European Commission. Good Manufacturing Practice for Medicinal Products. Council of Europe, Strasbourg, France (2010).
34. Koenig HC, Sutherland A, Izurieta HS, McGonagle D. Application of the immunological disease continuum to study autoimmune and other inflammatory events after vaccination. Vaccine 29(5), 913-919 (2011).
35. European Medicines Agency. Note for Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. CPMP/SWP/286/95 (2009).
36. Forster R. Study designs for the nonclinical safety testing of new vaccine products. J. Pharmacol. Toxicol. Methods 66(1), 1-7 (2012).
37. European Medicines Agency. Note for Guidance on Repeated Dose Toxicity. CPMP/SWP/1042/99 (2000).
38. Verdier F. Non-clinical vaccine safety assessment. Toxicology 174(1), 37-43 (2002).
39. Greisman SE, Hornick RB. Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc. Soc. Exp. Biol. Med. 131(4), 1154-1158 (1969).
40. Weingand K, Brown G, Hall R et al. Harmonization of Animal Clinical Pathology Testing in Toxicity and Safety Studies. Fundam. Appl. Toxicol. 29(2), 198-201 (1996).
41. Kaaijk P, van der Ark AA, van Amerongen G, van den Dobbelsteen GP. Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers. J. Appl. Toxicol. doi:10.1002/jat.2720 (2012) (Epub ahead of print).
42. Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25(16), 3080-3084 (2007).
43. Schindler S, von Aulock S, Daneshian M, Hartung T. Development, validation and applications of the monocyte activation test for pyrogens based on human whole blood. ALTEX 26(4), 265-277 (2009).
44. Hoffmann S, Peterbauer A, Schindler S et al. International validation of novel pyrogen tests based on human monocytoid cells. J. Immunol. Methods 298(1-2), 161-173 (2005).
45. Poole S, Mistry Y, Ball C et al. A rapid 'one-plate' in vitro test for pyrogens. J. Immunol. Methods 274(1-2), 209-220 (2003).
46. Duff GW, Atkins E. The detection of endotoxin by in vitro production of endogenous pyrogen: comparison with limulus amebocyte lysate gelation. J. Immunol. Methods 52(3), 323-331 (1982).
47. Stoddard MB, Pinto V, Keiser PB, Zollinger W. Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clin. Vaccine Immunol. 17(1), 98-107 (2010).
48. van der Ley P, van den Dobbelsteen G. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum. Vaccin. 7(8), 886-890 (2011).
49. Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect. Immun. 73(7), 4070-4080 (2005).
50. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23(17-18), 2222-2227 (2005).
51. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27( Suppl. 2), B112-B116 (2009).
52. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129(6), 1307-1326 (1969).
53. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129(6), 1327-1348 (1969).
54. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10(5), 780-786 (2003).
55. Oriente F, Scarlato V, Delany I. Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. J. Bacteriol. 192(3), 691-701 (2010).
56. Delany I, Grifantini R, Bartolini E, Rappuoli R, Scarlato V. Effect of Neisseria meningitidis fur mutations on global control of gene transcription. J. Bacteriol. 188(7), 2483-2492 (2006).
57. Giuntini S, Reason DC, Granoff DM. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect. Immun. 80(1), 187-194 (2012).
58. Jiang HQ, Hoiseth SK, Harris SL et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28(37), 6086-6093 (2010).
59. Shoemaker DR, Saunders NB, Brandt BL, Moran EE, Laclair AD, Zollinger WD. Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits. Infect. Immun. 73(8), 5031-5038 (2005).
60. Gioia CA, de Sousa AB, Cruz SC et al. Effect of a booster dose of serogroup B meningococcal vaccine on antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules. FEMS Immunol. Med. Microbiol. 44(1), 35-42 (2005).
61. Weynants VE, Feron CM, Goraj KK et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun. 75(11), 5434-5442 (2007).
62. Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197(7), 1053-1061 (2008).
63. Giuliani MM, Biolchi A, Serruto D et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28(31), 5023-5030 (2010).
64. Marzoa J, Sánchez S, Costoya L et al. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis. Vaccine 30(13), 2387-2395 (2012).
65. Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA 107(45), 19490-19495 (2010).
66. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77(2), 764-769 (2009).
67. Schneider MC, Prosser BE, Caesar JJ et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458(7240), 890-893 (2009).
68. Giuntini S, Reason DC, Granoff DM. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect. Immun. 79(9), 3751-3759 (2011).
69. Delgado M, Yero D, Niebla O et al. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate. Vaccine 25(50), 8420-8431 (2007).
70. Fukasawa LO, Dias WO, Schenkman RP, Raw I, Tanizaki MM. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice. FEMS Immunol. Med. Microbiol. 41(3), 205-210 (2004).
71. Koeberling O, Seubert A, Santos G et al. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29(29-30), 4728-4734 (2011).
72. Källström H, Liszewski MK, Atkinson JP, Jonsson AB. Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol. Microbiol. 25(4), 639-647 (1997).
73. Perkins-Balding D, Ratliff-Griffin M, Stojiljkovic I. Iron transport systems in Neisseria meningitidis. Microbiol. Mol. Biol. Rev. 68(1), 154-171 (2004).
74. Gorringe AR, Reddin KM, Funnell SG, Johansson L, Rytkonen A, Jonsson AB. Experimental disease models for the assessment of meningococcal vaccines. Vaccine 23(17-18), 2214-2217 (2005).
75. Li Y, Sun YH, Ison C, Levine MM, Tang CM. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci. Infect. Immun. 72(1), 345-351 (2004).
76. West D, Reddin K, Matheson M et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect. Immun. 69(3), 1561-1567 (2001).
77. Cox AD, Zou W, Gidney MA et al. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine 23(43), 5045-5054 (2005).
78. Szatanik M, Hong E, Ruckly C et al. Experimental meningococcal sepsis in congenic transgenic mice expressing human transferrin. PLoS ONE 6(7), e22210 (2011).
79. Zarantonelli ML, Szatanik M, Giorgini D et al. Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect. Immun. 75(12), 5609-5614 (2007).
80. Sjölinder H, Jonsson AB. Imaging of disease dynamics during meningococcal sepsis. PLoS ONE 2(2), e241 (2007).
81. Johansson L, Rytkonen A, Bergman P et al. CD46 in meningococcal disease. Science 301(5631), 373-375 (2003).
82. Johansson L, Rytkönen A, Wan H et al. Human-like immune responses in CD46 transgenic mice. J. Immunol. 175(1), 433-440 (2005).
83. Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, Granoff DM. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect. Immun. 80(2), 643-650 (2012).
84. Santolaya ME, O'Ryan ML, Valenzuela MT et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a Phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379(9816), 617-624 (2012).
85. Pinto VB, Moran EE, Cruz F et al. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 29(44), 7752-7758 (2011).
86. Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29(7), 1413-1420 (2011).
87. Rosenqvist E, Høiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63(12), 4642-4652 (1995).
88. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines 8(7), 851-861 (2009).
89. Post DM, Zhang D, Eastvold JS, Teghanemt A, Gibson BW, Weiss JP. Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J. Biol. Chem. 280(46), 38383-38394 (2005).
90. Zughaier S, Steeghs L, van der Ley P, Stephens DS. TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A. Vaccine 25(22), 4401-4409 (2007).
91. Guthrie T, Wong SY, Liang B et al. Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis. Infect. Immun. 72(5), 2528-2537 (2004).
92. Steeghs L, Tommassen J, Leusen JH, van de Winkel JG, van der Ley P. Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J. Endotoxin Res. 10(2), 113-119 (2004).
93. Sanders H. Investigation of the potential of PorA and FetA as meningococcal vaccine components. DPhil thesis, University of Oxford, Oxford, UK (2012).